Daily PubMed evidence board
Efficacy and Safety of Romiplostim in the Treatment of Aplastic Anemia: A Systematic Review and Single-Arm Meta-Analysis.
This paper pooled 19 studies (382 patients) that treated people with aplastic anemia using romiplostim, a drug that stimulates platelet production. The an…
Signal score51Research triage score
CertaintyLowVerify in full text
PMID42268485Source identifier
Research triage, not medical advice
Do not use this summary, score, or benefit-cost estimate to diagnose, treat, prescribe, or change care without reviewing the full study and consulting qualified professionals.
Verify before acting
Check full-text methods, eligibility, outcomes, risk of bias, harms, conflicts, funding, replication, and applicability.
Plain-English signal
This paper pooled 19 studies (382 patients) that treated people with aplastic anemia using romiplostim, a drug that stimulates platelet production. The analysis found an overall response rate of 72.4% and a complete response rate of 25.5%. Higher responses were seen with a 20 µg/kg dose compared with 10 µg/kg, and in patients younger than 60 years. Few patients stopped treatment and no deaths were reported as treatment-related in the included studies. Because the pooled studies were single-arm (no control groups) and varied in methods, these results are a promising signal but not definitive proof that romiplostim is better than current treatments.
Why it matters
- Aplastic anemia (AA) is a life-threatening bone marrow failure syndrome; romiplostim is a TPO receptor agonist under investigation as a therapeutic option for AA where effective treatments are limited.
- This pooled analysis reports overall response (ORR) and complete response rates (CRR) across 19 studies (382 patients), providing an aggregated signal on efficacy and safety that could inform research prioritization and trial design.
- The study suggests dose-related and age-related differences (higher ORR/CRR with 20 µg/kg and in patients <60 years), which may guide dosing hypotheses and subgroup analyses in future controlled trials.
Primary outcomes
- Overall response rate (ORR)
- Complete response rate (CRR)
Effect summary
Pooled ORR 72.4% (95% CI: 61.9%-81.9%); pooled CRR 25.5% (95% CI: 18.4%-33.1%). Reported higher ORR (77.6% vs 51.7%) and CRR (29.3% vs 17.0%) with 20 µg/kg versus 10 µg/kg; higher ORR in patients <60 years (74.9% vs 49.3%). Low discontinuation rate (2.1%) and no treatment-related deaths reported in pooled studies.
Benefit-cost lens
| Quick take | This systematic review and single-arm meta-analysis reports promising response rates for romiplostim in AA, but evidence is from non-randomized, single-arm studies; benefit-cost claims need absolute baseline risks, costs, and implementation details before policy or clinical change. |
|---|---|
| BCR anchor | 1 |
| Time horizon | 3 |
| Discount rate | 0.03 |
| Assumptions | Assumes pooled single-arm response rates reflect treatment-attributable effects, which is uncertain without controlled comparisons; full text review required to confirm patient selection, prior therapies, and outcome definitions. |
Benefit-cost fields are assumptions-based unless explicitly source-derived. Treat them as prompts for deeper economic review.
Risk of bias
| Tool | NOS/MINORS (as reported) + rapid abstract appraisal |
|---|---|
| Verdict | Higher uncertainty |
| Notes | The included evidence is from non-randomized, single-arm studies pooled in a meta-analysis. Abstract-level screening cannot confirm study-level bias domains (selection, confounding, outcome ascertainment, selective reporting). The authors reported using NOS and MINORS for quality assessment, but absence of randomized controlled data and potential heterogeneity across small studies increase risk of bias. |
Harms, equity, conflicts & implementation
| Implementation | Before implementation: full-text review, evaluation in randomized controlled trials or high-quality comparative studies, cost and supply analysis for romiplostim, clinician training for dosing/monitoring, and monitoring systems for adverse events and long-term outcomes. |
|---|---|
| Equity impact | Unclear from abstract. Equity implications depend on access to romiplostim, cost, and whether subgroups (age, comorbidity, geographic/ethnic groups) have differential responses or access-full-text and subgroup reporting needed. |
| Harms | Abstract reports low discontinuation (2.1%) and no treatment-related deaths; detailed adverse event profiles, grade, and longer-term harms are not reported in the abstract and require full-text review. |
| Funding | NO. 15882026XCZX012 Fundamental Research Funds for the Central Universities; 220601164154747 Education and Industry Collaboration in Joint Training Program; 220601164013611 Education and Industry Collaboration in Joint Training Program |
| Replication | Unknown from abstract-level triage; replication across randomized or controlled studies not established. |
Source links — verify original
Use PubMed and full-text links to confirm methods, population, outcomes, harms, conflicts, and applicability.